Orbimed Advisors reduced stake in Alpine Immune Sciences, Inc.

Orbimed Advisors reduced stake in Alpine Immune Sciences, Inc.

© Reuters.  Orbimed Advisors reduced stake in Alpine Immune Sciences, Inc. © Reuters. Orbimed Advisors reduced stake in Alpine Immune Sciences, Inc.

On the 28th of December, Orbimed Advisors sold 600 thousand Alpine Immune Sciences, Inc. (NASDAQ:ALPN) shares for $8.6 million at an average price of $14.25 per share. Shares of Alpine Immune Sciences, Inc. are down -49.03% since the transaction.

Orbimed Advisors's holding in Alpine Immune Sciences, Inc. decreased to about 3.1 million shares with the transaction.

Orbimed Advisors first bought Alpine Immune Sciences, Inc. stock in the third quarter of 2017. Orbimed Advisors also owns Bristol-Myers Squibb Co (NYSE:BMY), Merck (MRK), Larimar Therapeutics, Inc. (LRMR) and Mirati Therapeutics Inc (NASDAQ:MRTX). Alpine Immune Sciences, Inc. is its number twenty four position by number of shares and market value among biotechnology & life sciences stocks.

Contrary to Orbimed Advisors, Farallon Capital Management and Millennium Management established new holdings in Alpine Immune Sciences, Inc.

Original Article

Leave a comment

Send a Comment

Your email address will not be published. Required fields are marked *